



(51) International Patent Classification:

C07D 487/04 (2006.01) *A61P 31/00* (2006.01)
A61K 31/519 (2006.01) *A61P 37/00* (2006.01)
A61P 35/00 (2006.01) *A61P 29/00* (2006.01)
A61P 25/00 (2006.01) *A61P 3/00* (2006.01)

(21) International Application Number:

PCT/EP2012/005358

(22) International Filing Date:

21 December 2012 (21.12.2012)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

12000558.2 28 January 2012 (28.01.2012) EP

(71) Applicant: **MERCK PATENT GMBH** [DE/DE]; Frankfurter Strasse 250, 64293 Darmstadt (DE).

(72) Inventors: **DORSCH, Dieter**; Koenigsberger Strasse 17A, 64372 Ober-Ramstadt (DE). **HOELZEMANN, Guenter**; Gutenbergstrasse 6B, 64342 Seeheim-Jugenheim (DE). **SCHIEMANN, Kai**; Am Roedergraben 8, 64342 Seeheim-Jugenheim (DE). **WEGENER, Ansgar**; Koenigsbergerstrasse 12, 63150 Heusenstamm (DE).


(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES



(I)

(57) Abstract: Compounds of the formula (I) in which R1 and R2 have the meanings indicated in Claim 1, are inhibitors of GCN2, and can be employed, inter alia, for the treatment of cancer.